Sobre la capacidad discriminativa de diferentes autoanticuerpos en el diagnóstico del Lupus Eritematoso Sistémico

Damelia Echevarría Martínez; Helena Kokuina; Yahima Peña; Sergio Santana Porbén; Delsy Marrero Hernández

doi:10.19230/jonnpr.3657

Authors

Damelia Echevarría Martínez Médico, Especialista de Primer Grado en Laboratorio Clínico. Servicio de Laboratorio Clínico. Hospital Clínico quirúrgico “Hermanos Ameijeiras”. Centro Habana. La Habana. Cuba
Helena Kokuina Médico, Especialista de Segundo Grado en Inmunología Clínica. Sección de Inmunología del Servicio de Laboratorio Clínico. Hospital Clínico quirúrgico “Hermanos Ameijeiras”. Centro Habana. La Habana. Cuba
Yahima Peña Licenciada en Bioquímica. Sección de Inmunología del Servicio de Laboratorio Clínico. Hospital Clínico quirúrgico “Hermanos Ameijeiras”. Centro Habana. La Habana. Cuba
Sergio Santana Porbén Médico, Especialista de Segundo Grado en Bioquímica Clínica. Profesor Asistente. Servicio de Laboratorio Clínico. Hospital Pediátrico “Juan Manuel Márquez”. Marianao. La Habana. Cuba
Delsy Marrero Hernández Médico, Especialista de Primer Grado en Inmunología Clínica. Profesora instructora. Cuba

DOI:

https://doi.org/10.19230/jonnpr.3657

Keywords:

Systemic Lupus Erythematosus, Autoantibodies, Operational characteristics, ROC curve

Abstract

Rationale. Several autoantibodies have been proposed for the differential diagnosis of Systemic Lupus Erythematosus (SLE). Use of these autoantibodies might result in different operational characteristics.

Objective. To assess the operational characteristics of selected autoantibodies in the differential diagnosis of SLE.

Study design. Retrospective, analytical.

Study serie. One-hundred and sixty-nine subjects (SLE: 35.5 %; Non-SLE diseases of connective tissue: 38.5 %; Apparently healthy subjects: 26.0 %; Women: 84.6 %; Average age: 30.9 ± 17.9 years; Average evolution time of lupic disease: 3.9 ± 4.7 years).

Methods. Anti-double stranded DNA (anti-dsDNAdc), anti-nucleosomes (anti-Nuc), anti-Smith protein (anti- Sm) and anti-ribosomes (anti-Rib) autoantibodies were determined by immunoenzymatic techniques (Orgentec Diagnostika, Mainz, Alemania). Anti-nuclear antibodies (ANA) were indistinctely determined either by immunoenzimatic techniques (ANA-EIA) or immunofluorescent methods with Hep2 cells (ANAHep2). Operational characteristics of the autoantibodies in the differential diagnosis of SLE were calculated. In addition, corresponding ROC curves for each instance of analysis were obtained, and diagnostic accuracy was estimated from the area under the ROC curve (AROC).

Results. Accuracy of the autoantibodies used in the differential diagnosis of SLE was as follows (in descending order): anti-dsDNA: 0.9528 ± 0.0288; anti-Nuc: 0.7851 ± 0.0675; ANA-EIA: 0.7755 ± 0.2633; anti-Sm: 0.5926 ± 0.0790; anti-Rib: 0.5770 ± 0.2641; and ANA-Hep2: 0.5341 ± 0.2635; respectively. With the exception of anti-dcDNA, operational characteristics of the remaining antibodies were dependent upon cut-off value, sampled subpopulation, and analytical method.

Conclusions. anti-dsDNA antibodies were the most accurate in the differential diagnosis of SLE.

Downloads

Download data is not yet available.

References

Boumpas DT, Bertsias GK, Fanouriakis A. 2008–2018: A decade of recommendations for systemic lupus erythematosus. Ann Rheum Dis 2018;77:1547-8.

Colmán IA, Ávila G, Acosta ME, Aquino A, Centurión O, Duarte M. Manifestaciones clínicas y laboratoriales en el Lupus Eritematoso Sistémico-LES. Mem Inst Investig Cienc Salud 2016;14(1):0-0. Disponible en: https://revistascientificas.una.py/index.php/RIIC/article/view/780. Fecha de última visita: 5 de Mayo del 2020.

Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: An update. Curr Op Rheumatol 2018;30:144- 53.

Izquierdo JA, Martínez NC, Ochaita PL. Características epidemiológicas de los pacientes con lupus eritematoso cutáneo. Actas Dermo-Sifiliográficas 2014;105:69-73.

Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long‐term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: A fiveyear analysis of a large Medicaid population. Arthritis Care Res 2009;61:755-63.

Khamashta MA, Bruce IN, Gordon C, Isenberg DA, Ateka-Barrutia O, Gayed M; et al. The cost of care of systemic lupus erythematosus (SLE) in the UK: Annual direct costs for adult SLE patients with active autoantibody-positive disease. Lupus 2014;23:273-83.

Cervera R, Rúa-Figueroa I, Gil-Aguado A, Sabio JM, Pallarés L, Hernández-Pastor LJ, Iglesias M. Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: The LUCIE study. Rev Clín Esp 2013;213:127-37.

Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D; et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: An international collaboration. Arthritis Care Res 2018;70:571-81.

Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F; et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis 2018;77:1549-57.

Yaniv G, Twig G, Shor DBA, Furer A, Sherer Y, Mozes O, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: A diversity of 180 different antibodies found in SLE patients. Autoimm Rev 2015;14:75-9.

Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J; et al. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: A systematic literature review and meta‐regression of diagnostic data. Arthritis Care Res 2018;70:428-38.

Willems P, De Langhe E, Westhovens R, Vanderschueren S, Blockmans D, Bossuyt X. Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: Pitfalls and opportunities. Ann Rheum Dis 2019;78(8):e76-e76. Disponible en: https://ard.bmj.com/content/78/8/e76.abstract. Fecha de última visita: 7 de Febrero del 2020.

Kokuina E. Autoanticuerpos como biomarcadores de actividad de la enfermedad del lupus eritematoso sistémico. Rev Cubana Med 2014;53(2): 201-23. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232014000200009&lng=es. Fecha de última visita: 7 de Febrero del 2020.

Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB. Development of anti‐dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001;54(1‐2):211-9.

Arroyo-Ávila M, Santiago-Casas Y, McGwin G, Cantor RS, Petri M, Ramsey-Goldman R; et al. Clinical associations of anti-Smith antibodies in PROFILE: A multi-ethnic lupus cohort. Clin Rheumatol 2015;34:1217-23.

Gheita TA, Abaza NM, Hammam N, Mohamed AAA, El-Gazzar II, Eissa AH. AntidsDNA titre in female systemic lupus erythematosus patients: Relation to disease manifestations, damage and antiphospholipid antibodies. Lupus 2018;27:1081-7.

Mummert E, Fritzler MJ, Sjöwall C, BentowC, Mahler M. The clinical utility of antidouble-stranded DNA antibodies and the challenges of their determination. J Immunol Meth 2018;459: 11-9.

Kokuina E, Estévez del Toro M, Gutiérrez Á, Ortiz A, Sánchez Y, Pérez Campos D. Anticuerpos antinucleares específicos y afectaciones orgánicas en 180 pacientes con lupus eritematoso sistémico. Rev Cuba Reumatol 2015;17(2):104-111. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962015000200002&lng=es. Fecha de última visita: 8 de Febrero del 2020.

Fernández Mesa TA, Sánchez Martínez C, Junco-Calzadilla, R., González, G. D. G., & Iglesias-González, I. M. (2016). Importancia diagnóstica de los anticuerpos antinucleares. Revista Cubana de Reumatología, 18(2), 192- 196. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962016000400004.

Fecha de última visita: 8 de Febrero del 2020.

Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.

Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Dec Making 2000;20:468-70.

Obuchowski NA, Bullen JA. Receiver operating characteristic (ROC) curves: Review of methods with applications in diagnostic medicine. Phys Med Biol 2018;63(7):07TR01-07TR01. Disponible en: https://iopscience.iop.org/article/10.1088/1361-6560/aab4b1/meta. Fecha de última visita: 7 de Febrero del 2020.

Spronk PE, Bootsma H, Kallenberg CG. Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Clin Rev Allergy Immunol 1998;16:211-8.

Aho KI, Koskela PE, Mäkitalo R, Heliövaara M, Palosuo TI. Antinuclear antibodies heralding the onset of systemic lupus erythematosus. J Rheumatol 1992;19:1377-9.

Bai Y, Tong Y, Liu Y, Hu H. Self‐dsDNA in the pathogenesis of systemic lupus erythematosus. Clin Exp Immunol 2018;191:1-10.

Rekvig OP. Anti‐dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. Clin Exp Immunol 2015;179:5-10.

Adams BB, Mutasim DF. The diagnostic value of anti-nuclear antibody testing.International Journal of Dermatology 2000;39(12):887-91. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365- 4362.2000.00109.x. Fecha de última visita: 7 de Febrero del 2020.

Meroni PL, Chan EK, Damoiseaux J, Andrade LEC, Bossuyt X, Conrad K; et al. Unending story of the indirect immunofluorescence assay on HEp-2 cells: Old problems and new solutions? Ann Rheum Dis 2019;78(6):e46-e46. Disponible en: https://ard.bmj.com/content/78/6/e46?utm_term=1-B&utm_content=americas&utm_campaign=alljjs&utm_medium=cpc&utm_source=trendmd. Fecha de última visita: 9 de Febrero del 2020.

Hoffman IEA, PeeneIVeys EM, Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002;48:2171-6.Disponible en:

http://www.clinchem.aaccjnls.org/content/48/12/2171.short. Fecha de última visita: 9 de Febrero del 2020.

Kidd K, Cusi K, Mueller R, Goodner M, Boyes B, Hoy E. Detection and identification of significant ANAs in previously determined ANA negative samples. Clin Lab 2005;51:517-21.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16285474. Fecha de última visita: 8 de Febrero del 2020.

Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman G, et al. Evaluation of the BioPlex 2200 ANA screen. Analysis of 510 healthy subjects: Incidence of natural/predictive autoantibodies. Ann NY Acad Sci 2005;1050(1):380-8.Disponible en: https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1313.120. Fecha de última visita: 10 de Febrero del 2020.

Cairns PA, McMillan SA, Crockard AD, Meenagh GK, Duffy EM, Armstrong DJ; et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 272–3. Disponible en: https://ard.bmj.com/content/62/3/272.short. Fecha de última visita: 7 de Febrero del 2020.

Min DJ, Kim SJ, Park SH, Seo YI, Kang HJ, Kim WU; et al. Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 2002;20:13-8.

Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005;38:47- 54.

Zieve GW, Khusial PR. The anti-Sm immune response in autoimmunity and cell biology. Autoimmun Rev 2003;2:235-40.

Agarwal S, Harper J, Kiely PDW. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus 2009;18:407-12.

Martinez-Cordero E, Martinez-Miranda E, Negrete-Garcia MC, Padilla A, Aguilar Leon DE. Anti-dsDNA and Sm autoantibodies in systemic lupus erythematosus. Clin Rheumatol 1992;11:341-5.

Kokuina E. Importancia de indicar e interpretar las pruebas de autoanticuerpos. Rev Cubana Med 2016;55(4):324-39. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232016000400007&lng=es. Fecha de última visita: 10 de Febrero del 2020.

Ghirardello A, Caponi L, FranceschiniF, Zampiere S, Quinzanini M, Bendo R; et. al. Diagnostic test for antiribosomal P protein antibodies: A comparative evaluation of immunoblotting and ELISA assays. J Autoimmun 2002;19(1-2):71-7. Disponible en: https://www.sciencedirect.com/science/article/pii/S0896841102905950. Fecha de última visita: 8 de Febrero del 2020.

Mahler M, Kessenbrock K, Szmyrka M; et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vacc Immunol 2006;13:77-83. Disponible en: http://cvi.asm.org/content/13/1/77.short. Fecha de última visita: 9 de Febrero del 2020.